Vinflunine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Vinflunine
Vinflunine.svg
Systematic (IUPAC) name
methyl (2β,3β,4β,5α,12β,19α)- 4-(acetyloxy)- 15-[(4R,6R,8S)- 4-(1,1-difluoroethyl)- 8-(methoxycarbonyl)- 1,3,4,5,6,7,8,9-octahydro- 2,6-methanoazecino[4,3-b]indol- 8-yl]- 3-hydroxy- 16-methoxy- 1-methyl- 6,7-didehydroaspidospermidine- 3-carboxylate
Clinical data
AHFS/Drugs.com International Drug Names
License data
Routes of
administration
Intravenous
Legal status
Legal status
  • ℞ (Prescription only)
Identifiers
CAS Number 162652-95-1 YesY
ATC code L01CA05 (WHO)
PubChem CID 10629256
ChemSpider 8804619
UNII 5BF646324K YesY
ChEBI CHEBI:90241
ChEMBL CHEMBL510329 N
Chemical data
Formula C45H54F2N4O8
Molar mass 816.92 g/mol
 NYesY (what is this?)  (verify)

Vinflunine (INN, trade name Javlor) is a novel fluorinated Vinca alkaloid[1] undergoing research for the treatment of bladder cancer. It was originally discovered by the team of the Professor Jean-Claude Jacquesy (UMR CNRS 6514 - Poitiers University),[2] developed by Laboratoires Pierre Fabre and was licensed to Bristol-Myers Squibb for development in certain countries, including the United States.

On November 23, 2007, Pierre Fabre and BMS announced that they are terminating their license agreement for the development of vinflunine.[3]

As of 2016 In some countries, vinflunine is the only commercially approved agent for salvage therapy of urothelial carcinoma, (with approval based on the results of a phase III trial), with a reported median OS of about 6 months.[4][5]

Approvals and indications[edit]

Clinical trials[edit]

It has undergone a phase III clinical trial for advanced transitional cell carcinoma of the urothelial tract.[5]

References[edit]

  1. ^ Kruczynski A, Barret JM, Etiévant C, Colpaert F, Fahy J, Hill BT (March 1998). "Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid". Biochem. Pharmacol. 55 (5): 635–48. doi:10.1016/S0006-2952(97)00505-4. PMID 9515574. 
  2. ^ Vinca Alkaloids in Superacidic Media: A Method for Creating a New Family of Antitumor Derivatives Fahy, J.; Duflos, A.; Ribet, J.-P.; Jacquesy, J.-C.; Berrier, C.; Jouannetaud, M.-P.; Zunino, F. J. Am. Chem. Soc.; (Communication); 1997; 119(36); 8576-8577.
  3. ^ "Bristol -Myers Squibb press release - Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status". Retrieved 2008-06-27. 
  4. ^ Systemic Therapy for Urothelial Carcinoma: Is a Renaissance Around the Corner? 2016
  5. ^ a b Bellmunt J, Theodore C, Demkov T; et al. (2009). "Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.". J Clin Oncol. 2009;27:4454-61. doi:10.1200/JCO.2008.20.5534.